This text of Illinois § 3.6 (Duchenne muscular dystrophy) is published on Counsel Stack Legal Research, covering Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
(a)Subject to appropriation, the Department shall provide all newborns with screening tests for the presence of Duchenne muscular dystrophy. The testing shall begin within 6 months after the occurrence of all of the following milestones:
(1)Unless the federal Food and Drug Administration approves a screening test for Duchenne muscular dystrophy using dried blood spots, the development and validation of a reliable methodology for screening newborns for Duchenne muscular dystrophy using dried blood spots and a methodology for conducting quality assurance testing of the screening test.
(2)The availability of any necessary reagent for a Duchenne muscular dystrophy screening test.
(3)The establishment and verification of relevant and appropriate performance specifications as defined under t
Free access — add to your briefcase to read the full text and ask questions with AI
(a) Subject to appropriation, the Department shall provide all newborns with screening tests for the presence of Duchenne muscular dystrophy. The testing shall begin within 6 months after the occurrence of all of the following milestones: (1) Unless the federal Food and Drug Administration approves a screening test for Duchenne muscular dystrophy using dried blood spots, the development and validation of a reliable methodology for screening newborns for Duchenne muscular dystrophy using dried blood spots and a methodology for conducting quality assurance testing of the screening test. (2) The availability of any necessary reagent for a Duchenne muscular dystrophy screening test. (3) The establishment and verification of relevant and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for Federal Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required. (4) The availability of quality assurance testing and comparative threshold values for Duchenne muscular dystrophy screening tests. (5) The acquisition and installation by the Department of equipment necessary to implement Duchenne muscular dystrophy screening tests. (6) The establishment of precise threshold values ensuring defined disorder identification of Duchenne muscular dystrophy. (7) The authentication of pilot testing indicating that each milestone described in paragraphs (1) through (6) has been achieved. (8) The authentication of achieving the potential of high throughput standards for statewide volume of each Duchenne muscular dystrophy screening test concomitant with each milestone described in paragraphs (1) through (4). (b) To accumulate the resources for the costs, including start-up costs, associated with Duchenne muscular dystrophy screening tests and any follow-up programs, the Department may require payment of an additional fee for administering a Duchenne muscular dystrophy screening test under this Section. The Department may not require the payment of the additional fee prior to 6 months before the Department administers Duchenne muscular dystrophy screening tests under this Section.